BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
29 juin 2020 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...
NOVARTIS logo.jpg
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
29 juin 2020 02h45 HE | Novartis International AG
Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
15 mai 2020 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported...
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
07 mai 2020 08h30 HE | ARCA biopharma, Inc.
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence °  26% reduction in total time spent...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
06 mai 2020 16h30 HE | ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
BioCardia-Final-Logo-2016-JPEG.jpg
BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED
31 mars 2020 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...
BioCardia-Final-Logo-2016-JPEG.jpg
BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL
12 mars 2020 08h00 HE | BioCardia, Inc.
Company to Host a Conference Call with National Co-Principal Investigators on March 31, 2020 at 4:15 p.m. ET Fourth Quarter 2019 Financial Results to be Issued March 30, 2020 SAN CARLOS, Calif.,...
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
18 févr. 2020 16h30 HE | ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF clinical trial initiation anticipated fourth...
54741_Image_jpeg.jpg
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th Congress
12 févr. 2020 08h00 HE | Daxor Corporation
New Data Scheduled for Presentation on Daxor’s BVA-100® NEW YORK, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation...
BioCardia-Final-Logo-2016-JPEG.jpg
Biocardia Announces FDA Clearance for Morph DNA Deflectable Guide Catheter
14 janv. 2020 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...